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Abstract
Background: The genetic and molecular basis of glutamatergic dysfunction is one key to understand schizophrenia, with
the identification of an intermediate phenotype being an essential step. Mismatch negativity (MMN) or its magnetic
counterpart, magnetic mismatch field (MMF) is an index of preattentive change detection processes in the auditory cortex
and is generated through glutamatergic neurotransmission. We have previously shown that MMN/MMF in response to
phoneme change is markedly reduced in schizophrenia. Variations in metabotropic glutamate receptor (GRM3) may be
associated with schizophrenia, and has been shown to affect cortical function. Here we investigated the effect of GRM3
genotypes on phonetic MMF in healthy men.
Methods: MMF in response to phoneme change was recorded using magnetoencephalography in 41 right-handed healthy
Japanese men. Based on previous genetic association studies in schizophrenia, 4 candidate SNPs (rs6465084, rs2299225,
rs1468412, rs274622) were genotyped.
Results: GRM3 rs274622 genotype variations significantly predicted MMF strengths (p=0.009), with C carriers exhibiting
significantly larger MMF strengths in both hemispheres compared to the TT subjects.
Conclusions: These results suggest that variations in GRM3 genotype modulate the auditory cortical response to phoneme
change in humans. MMN/MMF, particularly those in response to speech sounds, may be a promising and sensitive
intermediate phenotype for clarifying glutamatergic dysfunction in schizophrenia.
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Introduction
Synaptic pathology through glutamatergic dysfunction is a key
to understand the pathophysiology of schizophrenia [1]. Functions
of susceptibility genes for schizophrenia have converged to
synaptic plasticity and glutamatergic neurotransmission [2].
Postmortem studies have shown reduced spine density in
prefrontal and auditory cortices in schizophrenia [3,4].
Consistently observed reduction of mismatch negativity
(MMN) event-related potentials or its magnetic counterpart
(magnetic mismatch field; MMF), an index of auditory sensory
memory with a major generator in the auditory cortex, has
supported the hypothesis [5], since the generation of MMN is
regulated through the N-methyl-D-aspartate (NMDA) receptor
agonistic effect [6]. Thus, MMN/MMF may be a useful
intermediate phenotype to assess glutamatergic function in
schizophrenia.
MMN/MMF is also elicited by change in speech sounds [7],
which has been recognized as an index of language-specific
speech-sound traces and learning-induced short-term plasticity.
We have shown that phonetic MMN, rather than tonal MMN,
exhibited more marked reduction in schizophrenia [8]. We
replicated the findings using MMF [9]. Moreover, the reduced
MMF strengths were significantly associated with reduced left
planum temporale gray matter volume reduction in patients with
schizophrenia [10]. These results suggest that MMN/MMF in
response to phoneme change may be a promising candidate as an
intermediate phenotype of glutamate-related genes.
Metabotropic glutamate receptors, by augmenting the function
of, or co-acting with, NMDA receptors, are important in synaptic
plasticity [1]. Metabotropic glutamate receptor 3 (GRM3) may be
associated with schizophrenia phenotype [11–14], although
controversial [15,16]. Among studies reporting positive findings,
the polymorphisms showing association were totally different.
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(SNP) rs6465084 (hCV11245618) and a related haplotype are
associated with the disease in a U.S. population. The same SNP
was studied by Norton et al. [15], and no significant association was
observed. In Asians, Chen et al. [13] observed a significant
association of the SNP rs2299225 and a related haplotype with
schizophrenia in Chinese subjects. Fujii et al. [11] found an
association between rs1468412 and schizophrenia in their
Japanese study. Bishop et al. [14] has shown that GRM3
rs274622 modulated the effect of olanzapine on negative
symptoms in Caucasian patients with schizophrenia.
Moreover, GRM3 genotype modulates prefrontal BOLD signals
and N-Acetylaspartate (NAA) levels [12,17] and mGlu3 protein
levels were reduced in the prefrontal cortex in postmortem brains
of schizophrenia [18].
Accordingly, we predicted that phonetic MMF would be
modulated by variations in GRM3 in healthy subjects. Our
hypothesis stems from the facts: 1) we previously found more
marked reduction of phonetic MMN rather than tonal MMN in
patients with schizophrenia [8,9]; 2) phonetic MMN has been
recognized as an index of language-specific speech-sound traces
and learning-induced short-term plasticity [7]; 3) MMN is thought
to be a promising intermediate phenotype for glutamatergic
system which is involved in synaptic plasticity [5]. We addressed




Participants were 41 healthy Japanese men (mean age: 28.8+/
25.5 years). All participants were right-handed according to the
Edinburgh Inventory and were native Japanese speakers. The
average years of education of the subjects were 17.0 [SD=1.2];
the average IQ was 112.3 [SD=7.6]. For screening of healthy
subjects, SCID non-patient edition (SCID-NP) was used. Exclu-
sion criteria were neurological illness, hearing dysfunction,
traumatic brain injury with any known cognitive consequences
or loss of consciousness for more than 5 minutes, a history of
substance abuse or addiction. The ethical committee of the Faculty
of Medicine, University of Tokyo approved this study (No. 784-2
for MEG experiment; No. 639-9 for imaging-genetics project). All
subjects gave written informed consent after a complete explana-
tion of the study.
MEG recording and analysis
MEG recording and analysis was described in detail elsewhere
[19]. Briefly, the subjects were presented with sequences of
auditory stimuli to both ears, consisting of standard (Japanese
vowel /a/ with a 250-msec duration, 80 dB SPL and a rise/fall
time of 10 ms; probability=90%) and deviant (Japanese vowel /
o/ with a 250-msec duration, p=10%) stimuli. The stimulus onset
asynchrony was 445615 msec. Measurements were performed in
the early afternoon (from 2 p.m. through 3 p.m.). The subjects
were instructed to perform a visual detection task, in order to keep
attention away from the auditory stimuli. MEG signals were
recorded using VectorView (Elekta Neuromag, Helsinki, Finland),
which has 204 first-order planar gradiometers at 102 measuring
sites on a helmet-shaped surface that covers the entire scalp. The
recorded data were filtered online with a band-pass filter of 0.03–
100 Hz, digitalized at a sampling rate of 512 Hz, and averaged
online separately for standard and deviant stimuli. The duration of
the averaging period was 400 ms, including an 80-msec
prestimulus baseline. Trials with EOG movement exceeding
150 mV or MEG exceeding 3,000 fT/cm were excluded the
analysis. The number of accepted responses for deviant stimuli was
above 100 for all subjects. The averaged data were further filtered
offline with a band-pass filter of 1–20 Hz.
The MMF is defined as the difference between the evoked
magnetic fields of the standard stimuli and those of the deviant
tone. The strength of MMF was indexed by the magnetic
counterpart of the global field power (mGFP), which was
calculated as the root mean squares of the differences over the
54 channels positioned over the temporal region, separately for
each hemisphere [9,20].
Genotyping
Genotyping procedures were also described in detail elsewhere
[16]. Briefly, genomic DNA was extracted from leukocytes by
using the standard phenol-chloroform method. Based on previous
literature, we genotyped 4 candidate SNPs (rs6465084, rs2299225,
rs1468412, rs274622) of GRM3.
Statistical analysis
The mixed model repeated measures analysis of variance
(ANOVA) was performed on the mGFPs of MMF, adopting the
genotype as a between-subject factor and the hemisphere as a
within-subject factor. For rs6465084, AA subjects (N=33) and AG
subjects (N=8) were compared; for rs2299225, TT subjects
(N=33) and TG subjects (N=8) were compared; for rs1468412,
AA subjects (N=25) and AT/TT subjects (N=16 [AT=15/
TT=1]) were compared; for rs274622, CC/CT subjects (N=19
[CC=2/CT=17]) and TT subjects (N=22) were compared. The
threshold for statistical significance was set at p,0.0125 based on
the Bonferroni correction.
Results
Figure 1 shows grand mean mGFP waveforms of MMF averaged
for each GRM3 rs274622 genotype group for each hemisphere.
The repeated measures ANOVA showed a significant main effect of
GRM3 rs274622 genotype (F[1,39]=7.59, p=0.009), with no
genotype X hemisphere interaction (F[1,39]=0.036, p=0.85). The
GRM3 rs274622 C carriers (CC+TC) exhibited significantly larger
mGFP values in both hemispheres compared to the TT subjects
(post-hoc t-tests: left hemisphere: t[39]=2.20, p=0.034; right
hemisphere: t[39]=2.41, p=0.021). Demographic (age, education,
IQ, handedness), behavioral (sleepiness, response time and hit rate
for visual task), and MEG (the number of accepted sweeps for
deviant stimuli, MMF peak latency) variables did not significantly
differ between the genotypes (p’s.0.32).
Variations in the other 3 SNPs did not significantly influence
individual differences in MMF (main effect of genotype: p’s.0.17).
Discussion
Variations in GRM3 rs274622 genotype are associated with
individual differences in phonetic MMF power in the bilateral
auditory cortices. To our knowledge, this is the first report that
demonstrates the association between variations in a glutamate-
related gene and individual differences in MMN/MMF in humans.
These results confirm that MMF generation is regulated through
glutamatergic neurotransmission and suggest that MMN/MMF
may be a useful intermediate phenotype for genes coding the
glutamatergic system in humans and possibly in patients with
schizophrenia. In patients with schizophrenia, progressive decrease
of gray matter volume of the superior temporal gyrus and
MMN could concurrently occur [21,22]. Therefore, the association
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some extent in patients with schizophrenia. In this sense, MMF
could be considered as both trait and state markers in schizophre-
nia. In contrast, young healthy subjects do not exhibit markedly
progressive decline in these indices. Thus, MMF could be a
relatively robusttrait markerand the significant association between
gene and intermediate phenotype could be predicted more clearly.
Bishop et al. [14] found that improvement in negative
symptoms when treated with olanzapine was significantly greater
in patients with schizophrenia who carry C allele of GRM3
rs274622 than in TT subjects. Taken together with the present
findings, this SNP may be functionally relevant for cortical
synaptic plasticity.
Our research group has previously demonstrated that effect size
of the difference between healthy subjects and schizophrenia is
larger for phonetic MMN/MMF than for tonal MMN/MMF
[8,9]. Thus, phonetic MMN/MMF may be a particularly sensitive
intermediate phenotype for clarifying the molecular pathway of
the glutamate system in the pathophysiology of schizophrenia.
Limitations of this study include small sample size and limited
number of genes and SNPs investigated, and data on patients with
schizophrenia being unavailable. Our next step should be a
multivariate analytic approach to understand the complex
relationship between various types of MMN/MMF and genes
related to the glutamatergic system and synaptic plasticity
identified through a genome-wide search in the general population
and its alteration in patients with schizophrenia.
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Figure 1. Grand mean mGFP waveforms of MMF. These waveforms were averaged for each GRM3 rs274622 genotype group for each
hemisphere (C carriers [N=19], solid line; TT individuals [N=22], dashed line).
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